There’s one born every minute – or that, at least, is what Nestlé’s latest acquisition implies. The Swiss food group is paying a hefty $12bn for Pfizer’s infant nutrition business. At first that looks a rich price for the US pharmaceutical group’s Pfizer Nutrition unit, which makes milk formula. But then, 85 per cent of its sales are to emerging markets. And Nestlé knows that the latter account for almost three-quarters of the $30bn global baby food market, which is growing at about 10 per cent a year. China is expected to account for almost half that growth. Asia does make the dealcompelling. Even so, it is hard to escape the impression that Pfizer has somehow injected some Viagra into the deal.
每分钟都有一个人出生——或者，这至少是雀巢公司(Nestlé)最新收购行动所暗示的那样。该瑞士食品集团为购买辉瑞公司(Pfizer)的婴儿营养品业务支付了120亿美元巨款。乍一看，是这家美国制药集团高价出售了主要生产配方奶粉的营养品业务。可话说回来，其85%的销售面向新兴市场。而雀巢公司清楚知道，后者占有总值300亿美元、且每年增长大约10%的manbetx app苹果 婴儿食品市场近四分之三的份额。预计其中一半增长来自manbetx3.0 。亚洲市场的格局确实让这场交易令人信服。但即便如此，人们难免留下这样一种印象，即辉瑞以某种方式向这场交易注入了一种类似“伟哥”的东西。